公开(公告)号：US11999694B2

公开(公告)日：2024-06-04

申请号：US17976150

申请日：2022-10-28

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker ,  Michael S. Placzek

IPC: C07D209/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D475/04 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D519/00 ,  C07F7/18

CPC classification number: C07D209/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D475/04 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D519/00 ,  C07F7/1804

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

公开(公告)号：US20250051277A1

公开(公告)日：2025-02-13

申请号：US18705647

申请日：2022-10-28

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker ,  Michael S. Placzek

IPC: C07D209/12 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

公开(公告)号：US20250011281A1

公开(公告)日：2025-01-09

申请号：US18812309

申请日：2024-08-22

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker ,  Michael S. Placzek

IPC: C07D209/12 ,  A61K31/404 ,  C07D405/04

Abstract: Disclosed are compounds that are derivatives of mesembranol or mesembrenol, and related methods of preparing and using these compounds. The disclosed compounds may inhibit SERT.

公开(公告)号：US20240400508A1

公开(公告)日：2024-12-05

申请号：US18799074

申请日：2024-08-09

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker

IPC: C07D209/12 ,  A61K31/404

Abstract: Disclosed are compounds that are alkylated derivatives of mesembrine or mesembrenone, and related methods of preparing and using these compounds. The disclosed compounds may inhibit PDE4 and/or the serotonin transporter protein (5-HTT).

公开(公告)号：US20240398759A1

公开(公告)日：2024-12-05

申请号：US18807015

申请日：2024-08-16

Applicant: Sensorium Therapeutics, Inc.

Inventor： Michael S. Placzek ,  Jacob M. Hooker

IPC: A61K31/404 ,  A61P25/24

Abstract: Disclosed are compositions comprising mesembranol, such as (−) mesembranol or (−) 6-epi-mesembranol. The disclosed compositions can be used in methods of inhibiting SERT. Methods of treatment for anxiety or depression are also provided, including methods comprising the oral administration to a subject in need thereof a therapeutically effective amount of certain pharmaceutical compositions.

公开(公告)号：US20240246910A1

公开(公告)日：2024-07-25

申请号：US18405058

申请日：2024-01-05

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker ,  Michael S. Placzek

IPC: C07D209/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D475/04 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D519/00 ,  C07F7/18

CPC classification number: C07D209/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D475/04 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D519/00 ,  C07F7/1804

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

公开(公告)号：US20250059156A1

公开(公告)日：2025-02-20

申请号：US18799037

申请日：2024-08-09

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker ,  Michael S. Placzek

IPC: C07D401/04 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4155 ,  A61K31/454 ,  A61K31/5377 ,  C07D209/12 ,  C07D209/70 ,  C07D403/04 ,  C07D413/04 ,  C07D491/044 ,  C07D491/107

Abstract: Disclosed are compounds that are derivatives of mesembrine or mesembrenone, and related methods of preparing and using the compounds. The disclosed compounds inhibit PDE4.

公开(公告)号：US20240408119A1

公开(公告)日：2024-12-12

申请号：US18799146

申请日：2024-08-09

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker ,  Michael S. Placzek

IPC: A61K31/675 ,  A61K9/08 ,  A61K31/404 ,  A61K31/665 ,  C07D209/12 ,  C07F9/6574 ,  C07F9/6584

Abstract: Disclosed are compounds that can be converted to mesembrine under physiologically relevant conditions, and related methods of preparing and using the compounds.

公开(公告)号：US20230159455A1

公开(公告)日：2023-05-25

申请号：US17976150

申请日：2022-10-28

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker ,  Michael S. Placzek

IPC: C07D209/12 ,  C07D491/113 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D491/20 ,  C07D401/12 ,  C07D519/00 ,  C07D495/04 ,  C07D475/04 ,  C07D405/12 ,  C07D409/12 ,  C07F7/18

CPC classification number: C07D209/12 ,  C07D491/113 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D491/20 ,  C07D401/12 ,  C07D519/00 ,  C07D495/04 ,  C07D475/04 ,  C07D405/12 ,  C07D409/12 ,  C07F7/1804

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.